rttnews.comOCT 132 min read$GMAB

Genmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over Year

Genmab (GMAB) reported $4.24B in Q3 2026 DARZALEX sales, up 15% YoY from $3.67B in Q3 2025, driven by increased adoption. U.S. sales were $2.53B, international sales $1.71B. DARZALEX is a multiple myeloma treatment marketed with JNJ. GMAB stock closed at $37.37, up 0.81%.

Original reporting

rttnews.com

Published Oct 13, 2026, 11:25 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 13, 2026, 11:35 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$GMAB

Bullish

high confidence

Mentioned

$GMAB

Relevance

8/10

AlphAI data visualization · based on rttnews.com

Decision brief

The 30-second read

$GMABBullishMed

Why it matters

The strong Q3 sales figure may prompt analysts to raise earnings forecasts for Genmab and could lift related oncology stocks.

Market read

First‑time disclosure of Q3 DARZALEX sales provides fresh material data for traders.

What to watch

Potential pricing pressure from biosimilar competition not discussed.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Genmab's royalty income from DARZALEX is a key revenue driver; the drug is co‑commercialized with Johnson & Johnson.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$GMABBullishHigh confidence

Context

Genmab reported Q3 2026 DARZALEX net sales of $4.24 billion, up 15% YoY, a fresh material revenue figure.

Expected impact

upward pressure as investors price in higher royalty revenue.

Evidence & confidence

The disclosed sales exceed prior quarter and show YoY growth; market typically rewards higher royalty income.

Market effects

Sector

Boosts outlook for biotech royalty partners and J&J's oncology franchise.

Regional

U.S. biotech stocks may see modest gains.

Global

Highlights strength of global multiple‑myeloma market.

Counterpoint

What could challenge this read

If sales growth slows in future quarters, the rally could be short‑lived.

Key entities

company
Genmab
Danish biotech firm receiving royalties from DARZALEX.
company
Johnson & Johnson
Partner commercializing DARZALEX.

Read at source ← All news

OCT 19

$GMABMedAI 8/10

Weekly Recap: EPCORE DLBCL-2 positive results and DARZALEX Q3 2026 sales

Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% compared to R-CHOP alone in the Phase 3 EPCORE DLBCL-2 trial. The company plans to present these results and share them with regulators. Additionally, Genmab announced Q3 2026 net sales of $4.239B for DARZALEX, generating royalties for the company.

tradingview.com1 min

OCT 19

$ZNTLMedAI 8/10

Zentalis Pharmaceuticals reports 15.8-month survival

Zentalis Pharmaceuticals (ZNTL) reported Phase 2 data showing 15.8-month median survival in Cyclin E1-positive ovarian cancer patients treated with azenosertib. The study lacked a chemotherapy control group. Shares fell 4.91% to $2.13 before the announcement. Zentalis expects topline DENALI Part 2 results in 1H 2027 and has sufficient cash to fund operations into late 2027.

mugglehead.com2 min

OCT 14

$ONCYMed

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

prnewswire.com3 min

OCT 13

$GMABMed

Genmab A/S (GMAB) Q3 DARZALEX Net Sales $4.24B

Genmab reported Q3 2026 DARZALEX net sales of $4.24B, with $2.53B in the U.S. and $1.71B rest of world, according to J&J. Genmab earns royalties on these sales, which are a key revenue driver.

tradingview.com1 min

OCT 7

$GMABHighAI 8/10

H.C. Wainwright raises Genmab stock price target on positive trial data

H.C. Wainwright raised its price target for Genmab (GMAB) to $50 from $40, citing positive Phase 3 trial results for EPKINLY. The stock is up 23% YTD. Genmab reported Q2 2026 earnings of $4.91 per share, beating estimates, and raised its 2026 revenue guidance. Guggenheim also increased its price target to $54.

uk.investing.com2 min

OCT 6

$ABBVHighAI 9/10

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Genmab and AbbVie's Epkinly, combined with chemotherapy, reduced disease progression or death risk by 51% in a Phase 3 lymphoma trial. The results exceeded expectations and could boost Epkinly's sales. Genmab reported $312M in Epkinly sales in H1 2024, and its shares rose 14% on the news. Epkinly may become the first drug of its kind approved for first-line DLBCL.

finance.yahoo.com2 min